CureVac N.V.’s (CVAC) Stock: A -6.41% Simple Moving Average for the Past 20 Days

The stock of CureVac N.V. (CVAC) has gone down by -3.28% for the week, with a -11.41% drop in the past month and a -29.26% drop in the past quarter. The volatility ratio for the week is 4.63%, and the volatility levels for the past 30 days are 5.44% for CVAC. The simple moving average for the past 20 days is -6.41% for CVAC’s stock, with a -52.16% simple moving average for the past 200 days.

Is It Worth Investing in CureVac N.V. (NASDAQ: CVAC) Right Now?

Additionally, the 36-month beta value for CVAC is 2.50. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for CVAC is 91.60M and currently, short sellers hold a 5.30% ratio of that float. The average trading volume of CVAC on April 04, 2024 was 783.19K shares.

CVAC) stock’s latest price update

CureVac N.V. (NASDAQ: CVAC)’s stock price has plunge by 1.37relation to previous closing price of 2.91. Nevertheless, the company has seen a -3.28% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-01-26 that CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Analysts’ Opinion of CVAC

Many brokerage firms have already submitted their reports for CVAC stocks, with SVB Securities repeating the rating for CVAC by listing it as a “Outperform.” The predicted price for CVAC in the upcoming period, according to SVB Securities is $13 based on the research report published on June 08, 2023 of the previous year 2023.

UBS, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $18, previously predicting the price at $8. The rating they have provided for CVAC stocks is “Buy” according to the report published on January 19th, 2023.

Jefferies gave a rating of “Buy” to CVAC, setting the target price at $21 in the report published on January 09th of the previous year.

CVAC Trading at -12.11% from the 50-Day Moving Average

After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.13% of loss for the given period.

Volatility was left at 5.44%, however, over the last 30 days, the volatility rate increased by 4.63%, as shares sank -10.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.05% lower at present.

During the last 5 trading sessions, CVAC fell by -3.28%, which changed the moving average for the period of 200-days by -71.19% in comparison to the 20-day moving average, which settled at $3.14. In addition, CureVac N.V. saw -29.93% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CVAC

Current profitability levels for the company are sitting at:

  • -7.18 for the present operating margin
  • -2.52 for the gross margin

The net margin for CureVac N.V. stands at -7.05. The total capital return value is set at -0.44. Equity return is now at value -51.09, with -35.79 for asset returns.

Based on CureVac N.V. (CVAC), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.49. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -41.31.

Currently, EBITDA for the company is -223.1 million with net debt to EBITDA at 1.53. When we switch over and look at the enterprise to sales, we see a ratio of 4.36. The receivables turnover for the company is 1.97for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.56.

Conclusion

In conclusion, CureVac N.V. (CVAC) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts